Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Esomeprazole on Isavuconazole PK
NCT02128893Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of isavuconazole in invasive aspergillosis (IA) and mucormycosis (2 arms), sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve during the time interval between consecutive dosing at Day 10, Maximum plasma concentration at Day 10 and 5 more. Started Jan 2014; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on NCT02128893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128893.